BRAF-SEPT3 is a novel fusion discovered in one patient with melanoma and conferred the least proliferative but most invasive phenotype of the three BRAF fusions that were evaluated, as well as a low treatment response to MAPK inhibitors (Turner et al., 2019). This evidence concerns the gene SEPTIN3 and melanoma.